Skip to main content
. 2020 Jun 19;23(Suppl 1):e25499. doi: 10.1002/jia2.25499

Figure 2.

Figure 2

Projected outcomes from combined HIV/NCD diagnosis and management in Kenya. The intervention runs from 2019‐2023, screening 20% of the population on an annual basis for HIV, hypertension and diabetes. Panel A shows the annual number of people diagnosed with hypertension and/or diabetes. The intervention further provides treatment to a proportion of those diagnosed with HIV, hypertension and/or diabetes. Panel B shows the number of individuals receiving treatment for hypertension and/or diabetes over time. Costs are divided into two groups, including additional costs required for disease screening and treatment (Panel C) and costs saved by averting future CVD events (Panel D). ART, antiretroviral therapy; NCD, non‐communicable diseases; CVD, cardiovascular disease.